Valeant Pharmaceuticals International has completed the previously announced acquisition of Salix Pharmaceuticals.
Valeant Pharmaceuticals International has completed the previously announced acquisition of Salix Pharmaceuticals.
The Laval, Que.-based company paid about US$11.1 billion or $173 a share for Salix.
Salix is a specialty pharmaceutical company that offers gastroenterology treatments.
As a result of the deal, Salix will become a wholly owned subsidiary of Valeant.
Also read:
On June 6, Benefits Canada hosted its annual Mental Health Summit, the industry’s most popular and well-known conference in this space. Designed for employers and the advisors...
While self-management strategies for mental health can empower plan members, plan sponsors also have a role to play in creating a work environment that’s conducive...
People leaders and managers have an important role to play in the well-being of their team members, said Carmen Bellows, registered psychologist and director of...
It’s important for plan sponsors to educate employees about the benefits of a good night’s sleep, said Ken Porter, national sustainability director for the Mood...
More than a third (36 per cent) of Canadian workers have been bothered by thoughts of death or self-harm over the past year, according to a...
During a panel at the Canadian Investment Review’s 2024 Global Investment Conference in April, three key thought leaders representing defined benefit pension plan sponsors shared...
Retirement plan members who engage with their plan digitally have an average retirement account balance 230 per cent higher than those who weren’t engaged ($123,800 versus $51,800), according to...
Nearly half (49 per cent) of executive leaders say financial stress often or very often prevents their frontline workers from doing their best work, according to...